UK Users

Access Prodigy topics and clinical content at the NICE website.

Visit the NICE website

Free Trial

To arrange a free trial of the Prodigy application, get in touch.

Contact us to arrange a trial

International Users

The Prodigy application is available on a subscription basis.

Subscription types

Sample Topic: Asthma

Asthma : Last revised in December 2013


Leukotriene receptor antagonists

Prescribing a leukotriene receptor antagonist

  • The leukotriene receptor antagonists montelukast and zafirlukast are well tolerated and have few class-related adverse effects [GINA, 2006].
  • Zafirlukast has been associated with liver toxicity. If clinical symptoms or signs suggestive of liver dysfunction occur (for example anorexia, nausea, vomiting, right upper quadrant pain, fatigue, lethargy, flu-like symptoms, enlarged liver, pruritus, or jaundice), stop zafirlukast and immediately measure serum transaminases (in particular, serum alanine aminotransferase). Routine monitoring of liver function is not recommended [ABPI Medicines Compendium, 2004].
  • Use in children: montelukast is the only leukotriene receptor antagonist licensed for use in children (aged 6 months and older). A paediatric granule formulation is available, which can be swallowed or mixed with cold or room-temperature soft food and taken immediately [ABPI Medicines Compendium, 2007].
  • Use in pregnancy: do not start a leukotriene receptor antagonist during pregnancy. However, if a woman is already taking a leukotriene receptor antagonist and it is considered essential, treatment can be continued during pregnancy [SIGN and BTS, 2011].
    • In two small prospective studies no increase in the rates of congenital malformation, preterm birth, or low-birthweight was found. There have been several case reports of limb defects in women taking a leukotriene receptor antagonist during pregnancy, but a causal relationship has not been established [Schaefer et al, 2007].

Advice for patients

  • Advise people taking zafirlukast to seek medical advice in the event of persistent nausea, vomiting, malaise, or jaundice [BNF 53, 2007].
  • Advise the person that montelukast should not be used to relieve symptoms of an acute asthma exacerbation.